Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice

References

• Horner MJ, Ries RAG, Krapcho M, Neyman N, Aminou R, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. Available from URL: http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.
   Google Scholar
• Trivers KF, Sabatino SA, Stewart SL. Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer 2008; 123:1422 - 8; http://dx.doi.org/10.1002/ijc.23691; PMID: 18546259
   PubMed Web of Science ®Google Scholar
• Neuner G, Patel A, Suntharalingam M. Chemoradiotherapy for esophageal cancer. Gastrointest Cancer Res 2009; 3:57 - 65; PMID: 19461907
   PubMedGoogle Scholar
• Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33:369 - 85; http://dx.doi.org/10.1053/j.seminoncol.2006.04.003; PMID: 16890793
   PubMed Web of Science ®Google Scholar
• Settleman J, Kurie JM. Drugging the bad “AKT-TOR” to overcome TKI-resistant lung cancer. Cancer Cell 2007; 12:6 - 8; http://dx.doi.org/10.1016/j.ccr.2007.06.010; PMID: 17613432
   PubMed Web of Science ®Google Scholar
• Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9:962 - 72; http://dx.doi.org/10.1016/S1470-2045(08)70206-7; PMID: 18804418
   PubMed Web of Science ®Google Scholar
• Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009; 6:352 - 66; http://dx.doi.org/10.1038/nrclinonc.2009.62; PMID: 19483740
   PubMed Web of Science ®Google Scholar
• Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011; 6:707 - 15; http://dx.doi.org/10.1097/JTO.0b013e31820a3a6b; PMID: 21258250
   PubMed Web of Science ®Google Scholar
• Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103:253 - 62; http://dx.doi.org/10.1016/S0092-8674(00)00117-3; PMID: 11057893
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926 - 45; http://dx.doi.org/10.1101/gad.1212704; PMID: 15314020
   PubMed Web of Science ®Google Scholar
• Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009; 8:3831 - 7; http://dx.doi.org/10.4161/cc.8.23.10070; PMID: 19901542
   PubMed Web of Science ®Google Scholar
• Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010; 7:209 - 19; http://dx.doi.org/10.1038/nrclinonc.2010.21; PMID: 20234352
   PubMed Web of Science ®Google Scholar
• Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol 2009; 36:Suppl 3 S26 - 36; http://dx.doi.org/10.1053/j.seminoncol.2009.10.013; PMID: 19963097
   PubMedGoogle Scholar
• Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23:5314 - 22; http://dx.doi.org/10.1200/JCO.2005.66.130; PMID: 15955899
   PubMed Web of Science ®Google Scholar
• Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, et al, North American Brain Tumor Consortium and the National Cancer Institute. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005; 23:357 - 61; http://dx.doi.org/10.1007/s10637-005-1444-0; PMID: 16012795
   PubMed Web of Science ®Google Scholar
• Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006; 95:1148 - 54; http://dx.doi.org/10.1038/sj.bjc.6603419; PMID: 17031397
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27:3822 - 9; http://dx.doi.org/10.1200/JCO.2008.20.7977; PMID: 19581539
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Naomoto Y, Nobuhisa T, Okawa T, Takaoka M, Shirakawa Y, et al. Heparanase regulates esophageal keratinocyte differentiation through nuclear translocation and heparan sulfate cleavage. Differentiation 2006; 74:235 - 43; http://dx.doi.org/10.1111/j.1432-0436.2006.00072.x; PMID: 16759289
   PubMed Web of Science ®Google Scholar
• Ohara T, Takaoka M, Sakurama K, Nagaishi K, Takeda H, Shirakawa Y, et al. The establishment of a new mouse model with orthotopic esophageal cancer showing the esophageal stricture. Cancer Lett 2010; 293:207 - 12; http://dx.doi.org/10.1016/j.canlet.2010.01.017; PMID: 20153104
   PubMed Web of Science ®Google Scholar
• Ohara T, Takaoka M, Toyooka S, Tomono Y, Nishikawa T, Shirakawa Y, et al. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells. Cancer Sci 2011; 102:1344 - 9; http://dx.doi.org/10.1111/j.1349-7006.2011.01967.x; PMID: 21521416
   PubMed Web of Science ®Google Scholar
• Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008; 8:851 - 64; http://dx.doi.org/10.1038/nrc2501; PMID: 18846101
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21 - 35; http://dx.doi.org/10.1038/nrm3025; PMID: 21157483
   PubMed Web of Science ®Google Scholar
• Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006; 18:77 - 82; http://dx.doi.org/10.1097/01.cco.0000198021.99347.b9; PMID: 16357568
   PubMed Web of Science ®Google Scholar
• Boone J, Ten Kate FJ, Offerhaus GJ, van Diest PJ, Rinkes IH, van Hillegersberg R. mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy?. J Clin Pathol 2008; 61:909 - 13; http://dx.doi.org/10.1136/jcp.2008.055772; PMID: 18474542
   PubMed Web of Science ®Google Scholar
• Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett 2007; 253:236 - 48; http://dx.doi.org/10.1016/j.canlet.2007.01.026; PMID: 17360108
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Faivre S, Serova M, Raymond E. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?. Br J Cancer 2008; 99:1197 - 203; http://dx.doi.org/10.1038/sj.bjc.6604636; PMID: 18797463
   PubMed Web of Science ®Google Scholar
• Kapoor A, Figlin RA. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 2009; 115:3618 - 30; http://dx.doi.org/10.1002/cncr.24409; PMID: 19479976
   PubMed Web of Science ®Google Scholar
• Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, et al. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 2008; 68:2934 - 43; http://dx.doi.org/10.1158/0008-5472.CAN-07-6487; PMID: 18413763
   PubMed Web of Science ®Google Scholar
• Watanabe N, Takaoka M, Sakurama K, Tomono Y, Hatakeyama S, Ohmori O, et al. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo. Clin Cancer Res 2008; 14:4631 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-07-4755; PMID: 18628478
   PubMed Web of Science ®Google Scholar
• Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, et al. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells. Oncol Rep 2008; 20:1473 - 7; PMID: 19020730
   PubMed Web of Science ®Google Scholar